Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: ABI-007 (Abraxane)|DRUG: bevacizumab
Sponsor: Celgene